UK clinical trials - updated daily from ClinicalTrials.gov
Find clinical trials for allergies and immune conditions in the United Kingdom. Explore immunotherapy, challenge studies, and biologic treatments for allergic diseases.
Allergic diseases affect over 20 million people in the UK, with rates rising sharply. The UK has world-leading allergy research centres at Imperial College London, King's College London, and the University of Edinburgh. Clinical trials range from Phase 1 healthy volunteer studies testing new antihistamines and biologics, to challenge studies exposing volunteers to allergens under controlled conditions.
Major trial categories: antihistamine bioequivalence and drug interaction studies (healthy volunteers, £500-£2,000), biologic therapies for severe allergy (omalizumab, dupilumab — patient trials), allergen immunotherapy/desensitisation (peanut, pollen, dust mite), and challenge studies where volunteers are exposed to allergens to test new treatments. Phase 1 drug studies for allergy medications commonly recruit healthy volunteers.
The biologic revolution has transformed allergy treatment. Dupilumab (Dupixent) targets IL-4/IL-13 for atopic dermatitis and asthma. Omalizumab (Xolair) blocks IgE for severe asthma and chronic urticaria. New targets include TSLP, IL-33, and IL-5 for various allergic conditions. Many of these biologic trials recruit both patients and healthy volunteers for Phase 1 pharmacokinetic studies.
Active UK allergy trials include: next-generation antihistamines, oral immunotherapy for food allergies (peanut, egg, milk), biologic combinations for severe asthma with allergic features, allergen challenge models, microbiome-based therapies, and gene therapy for primary immunodeficiencies. Challenge studies at hVIVO and university units offer competitive compensation.
Free AI-powered matching - no signup required
Search allergy Trials →